Discovery of new Hsp90–Cdc37 protein–protein interaction inhibitors : in silico screening and optimization of anticancer activity

Dernovšek, Jaka (avtor), Gradišek, Nina (avtor), Zajec, Živa (avtor), Urbančič, Dunja (avtor), Cingl, Jernej (avtor), Goričan, Tjaša (avtor), Golič Grdadolnik, Simona (avtor), Tomašič, Tihomir (avtor)

The interaction between heat shock protein 90 (Hsp90) and Hsp90 co-chaperone cell-division cycle 37 (Cdc37) is crucial for the folding and maturation of several oncogenic proteins, particularly protein kinases. This makes the inhibition of this protein–protein interaction (PPI) an interesting target for developing new anticancer compounds. However, due to the large interaction surface, developing PPI inhibitors is challenging. In this work, we describe the discovery of new Hsp90–Cdc37 PPI inhibitors using a ligand-based virtual screening approach. Initial hit compounds showed Hsp90 binding, resulting in anticancer activity in the MCF-7 breast cancer cell line. To optimize their antiproliferative effect, 35 analogs were prepared. Binding affinity for Hsp90 was determined for the most promising compounds, 8c (K$_d$ = 70.8 μM) and 13g (K$_d$ = 73.3 μM), both of which interfered with the binding of Cdc37 to Hsp90. This resulted in anticancer activity against Ewing sarcoma (SK-N-MC), breast cancer (MCF-7), and leukemia (THP-1) cell lines in vitro. Furthermore, compounds 8c and 13g demonstrated the ability to induce apoptosis in the Ewing sarcoma cell line and caused a decrease in the levels of several known Hsp90 client proteins in MCF-7 cells, all without inducing the heat shock response.

• Jezik: Angleški jezik
• Ključne besede: protein 90 (Hsp90), inhibition of protein–protein interaction, virtual screening, ligand-based pharmacophore models
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: FFA - Fakulteta za farmacijo
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2024
• Št. strani: Str. 28347–28375
• Številčenje: Vol. 14, iss. 39
• PID: 20.500.12556/RUL-162175
• UDK: 615.4:54
• ISSN pri članku: 2046-2069
• DOI: 10.1039/D4RA05878J
• COBISS.SI-ID: 206551811
• Datum objave v RUL: 19.09.2024

Gradivo je del revije

• Naslov: RSC advances
• Založnik: RSC Publishing
• ISSN: 2046-2069
• COBISS.SI-ID: 2513252

Licence

• Licenca: CC BY 3.0, Creative Commons Priznanje avtorstva 3.0 Nedoločena
• Povezava: https://creativecommons.org/licenses/by/3.0/deed.sl
• Opis: Dovoljuje kopiranje in razširjanje vsebin v kakršnemkoli mediju in obliki. Dovoljuje remixanje, urejanje, predelava in vključevanje vsebine v lastna dela v vse namene, tudi komercialne. Primerno morate navesti avtorja, povezavo do licence in označiti spremembe, če so kakšne nastale. To lahko storite na kakršenkoli razumen način, vendar ne na način, ki bi namigoval na to, da dajalec licence podpira vas ali vašo uporabo dela. Ne smete uporabiti pravnih določil ali tehničnih ukrepov, ki bi pravno omejili ali onemogočilo druge, da bi storili karkoli, kar licenca dovoli.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: zaviralci interakcije protein-protein, virtualni pregled, farmakoforski modeli na osnovi ligandov, protein 90 (Hsp90), farmacevtska kemija